Preferred Label : VSV-GP-based Cancer Vaccine VSV-GP128;
NCIt synonyms : Vesicular Stomatitis Virus-GP-based Boosting Cancer Vaccine VSV-GP128;
NCIt definition : A boosting cancer vaccine comprised of the recombinant chimeric oncolytic vesicular
stomatitis virus (VSV) viral vector VSV-GP containing as of yet undisclosed peptide(s)
derived from as of yet undisclosed tumor-associated antigen(s) (TAAs) that are specific
for colorectal cancer (CRC) patients, with potential immunomodulating and antineoplastic
activities. Upon administration, VSV-GP-based cancer vaccine VSV-GP128 preferentially
replicates in tumor cells. Due to defective antiviral host defense mechanisms in tumor
cells, VSV-GP is able to replicate in tumor cells without interference. This induces
VSV-mediated cytolytic activity towards the tumor cells. In addition, following the
administration of the priming vaccine ATP128, the booster VSV-GP-based cancer vaccine
VSV-GP128 may serve to further expand and improve the phenotyping of antigen-specific
T-cells targeted to tumor cells expressing the undisclosed TAA(s), thereby further
killing tumor cells expressing the TAA(s). VSV, a single-stranded RNA virus belonging
to the genus Vesiculovirus of the family Rhabdoviridae, is relatively nonpathogenic
to healthy humans but is able to rapidly replicate in and induce apoptosis of tumor
cells. VSV-GP carries the envelope glycoprotein (GP) of the WE-HPI strain of the lymphocytic
choriomeningitis virus (LCMV) instead of the native VSV glycoprotein (G). VSV-GP does
not induce neutralizing antibodies to the vector itself, which may allow repeated
administration. VSV-GP is also not neurotoxic, while wild-type viruses are associated
with neural inflammation.;
Molecule name : VSV-GP128; VSV GP128;
NCI Metathesaurus CUI : CL1771889;
Origin ID : C183521;
UMLS CUI : C5666912;
Semantic type(s)
- concept_is_in_subset
